Key words: albuminuria; diabetes mellitus; diabetic nephropathy; glycosaminoglycans Background. Glycosaminoglycans (GAGs) play an important role in the physiopathology of diabetic nephropathy; they are essential for the maintenance of glomerular charge selectivity and their administration Introduction can reduce albuminuria in diabetic patients. Methods. Following a randomized block design, conDiabetic nephropathy (DN ) is a chronic, severe comtrolled versus placebo, we investigated, in insulinplication of diabetes, characterized at the beginning by dependent diabetic patients with micro-or macroalbumicroalbuminuria and predicting subsequent progresminuria, whether GAG therapy can influence an sion to overt nephropathy and increased mortality altered albumin excretion rate (AER). Thirty-six due to uraemic and/or cardiovascular death [1,2]. patients (18 micro-and 18 macroalbuminuric) were Twenty-five to 50 per cent of diabetic patients, both randomized to receive, during 5 days/week for 3 weeks, insulin-dependent (type 1) and non-insulin-dependent either a daily dose of 600 lipoproteinlipase releasing (type II ) suffer from this condition [3]. The pathogenunits (LRU ) of sulodexide by the i.m. route (9 micro-esis of DN is still unclear, with both the haemodynamic and 9 macroalbuminuric patients), or a matching i.m. hypothesis and a poor blood sugar regulation being placebo (9 micro-and 9 macroalbuminuric patients). unable to completely explain the causes of its developAll patients were followed-up for further 6 weeks. ment [4 ]. AER was evaluated before treatment, weekly during it Among the anatomical hallmarks of DN are the and every 3 weeks during follow-up.
I. Dedov et al. 2296 electrophoretic fractions, glycaemia, azotaemia, uricaemia, These data point to an important role of GAGs in blood creatinine, total cholesterol and triglycerides), glycosylthe physiopathology of DN: an abnormal GAG metaated haemoglobin (by HPLC with an automatic analyser), bolism has also been hypothesized to be the cause of and urinalysis were also monitored in all patients. such pathology [7, 8, 15] .
Statistical evaluation of data was performed by comparing
The protective effect of GAGs is primarily due to the two groups of micro-and macroalbuminuric patients their ability to modulate the function of different cell submitted to either treatment, taking as primary criterion types, influencing the synthesis and composition of the for efficacy assessment the behaviour of AER levels. The extracellular matrix [8, [15] [16] [17] [18] ; this action is not distribution of AER values was normalized by log transdependent on their antithrombotic or anticoagulant formation. Comparability of the two treatment groups during the study period ( T0-T9) was checked by analysis of variance activity. GAGs are furthermore essential for the integfor repeated measures, corrected by Bonferroni. Since the rity of the glomerular charge selectivity, due to their sample size was small, the differences between treatments properties of electrostatic repulsion [19, 20] . Taking and within groups were verified by means of non-parametric into consideration these factors and GAG ability to tests (Mann-Whitney U test and Friedman's ANOVA).
reduce albuminuria, we investigated whether sulodex-Furthermore, by means of one-way analysis of variance, the ide, a naturally occurring GAG containing a fast-homogeneity of variances of micro-and macroalbuminurics' moving heparin-like fraction by 80% and a dermatan data between treatments, at each control time, was verified. fraction by 20% [21 ] , is able to influence albumin
The lower level for statistical significance was set at 5%. excretion rate (AER) in type I diabetic patients with Values are presented as mean±SEM. All data analyses were micro and macroalbuminuria.
performed using the commercially available statistical software SPSS for Windows (v. 6.1.3).
Subjects and methods Results
Thirty-six insulin-dependent (type I ) diabetic subjects were randomly selected from the micro-and macro-albuminuric All patients completed the administration period showpatients attending our outpatient clinic, to take part in this ing a good compliance with treatments. During the study period all subjects followed their 15-20%) as evaluated by a dietician, and maintenance of the usual diet, without variation of individual insulin daily usual insulin therapy that yielded a satisfactory metabolic requirement; they did not show any variation of metacontrol.
bolic control and creatinine clearance (Table 2 ) . No Exclusion criteria were neoplasms, secondary hyperother therapies were prescribed. tension, severe liver, cardiac, or systemic disease, creatinine>150 mmol/l, hypersensitivity to mucopolysaccharTaking into consideration the macroalbuminurics' ides, HbA1c>9.5%, symptomatic urinary tract infections, population, in sulodexide-treated patients AER was haematuria, previous nephropathy, and laboratory or sono-found decreased at the end of the treatment ( T 3), but graphy findings suggesting nephropathies other than the again increased during follow-up ( Figure 1 ). By perdiabetic one.
forming a global analysis of the behaviour of this Following a randomized block design, patients were dis-parameter, a significant difference depending on treattributed between treatment with sulodexide ( Vessel Due F, ment could not be evidenced. By analysing, conversely, Alfa Wassermann S.p.A., Bologna, Italy (18 patients, 9 with the variations at each control time, statistically signimicro-and 9 with macroalbuminuria), at the dose of 600 ficant (P<0.05) changes from T3 to T9, due to the LRU ( 60 mg) by i.m. route, once a day, 5 days/week, for 3 treatment-with-time interaction, are pointed out.
weeks; or with placebo (2 ml ampoules containing saline; 18 patients, 9 with micro-and 9 with macroalbuminuria), at A different trend was registered in microalbuminthe same posology. A follow-up period of 6 weeks was urics ( Figure 2 ), in whom a global evaluation of results observed in all patients.
pointed to statistically significant (P<0.001) variations End-point of the study was AER monitoring: this was in the sulodexide group, due to both treatment and performed on a 24-h urine collection before treatment ( T0 ), the treatment-with-time interaction (P<0.01 from T1 weekly during it ( T1, T2 and T3), and at 3-week intervals to T9). The two groups of micro-and macroalbuminduring the follow-up ( T6 and T9). AER was assessed using urics, when performing the comparison of treatments, the nephelometric method on the biochemical analyser were homogeneous at T0. Also the analysis, through 'Abbot Spectrum' ( Abbot Laboratories, USA).
non-parametric tests, of the observed variations led to
Before the start and at the end of treatment, creatinine similar conclusions.
clearance, haematological and coagulative parameters ( blood count, PTT ), haematochemical tests (total proteins and their
In the 18 placebo-treated patients no statistically Sulodexide efficacy in diabetic patients with micro-and macroalbuminuria 2297 significant variations were observed during the study period both in the micro-and in the macroalbuminuric patients.
No statistically significant differences concerning blood pressure, haematological, haematochemical, and coagulative tests, and urinalysis, were observed after treatment with respect to basal values, within and between the two groups.
Discussion
The rationale for this study was based on previous results, collected in experimental models, supporting the hypothesis that GAG metabolism might have a pathogenetic role in the onset of diabetic nephropathy and that GAGs are effective in ameliorating the natural history of a number of nephropathies [7, 8, 15] . Diabetes leads to a generalized reduction of negative charge in the extracellular matrix and plasma membrane, reflecting qualitative changes in the composition of the membrane itself [19, 22] . On the other hand, GAGs and particularly HS [8 ] are involved in glomerular permeability for macromolecules; they are essential for the integrity of the glomerular charge selectivity, due to their property of electrostatic repulsion, that is responsible for the net negative charge [20 ] and prevents the filtration of the negatively charged albumin. It has been shown that the enzymatic removal of HS by heparinase, the neutralization of HS charge by cations, or the injection of a monoclonal antibody specific for GBM HS, all induce an increase of proteinuria [19, 23, 24] .
The decreased charge selectivity of GBM may also be the consequence of undersulphation and/or of altered content of GAGs [7, 8, 25 ] : in fact, in diabetes, GAG sulphation is abnormal. Results of experimental diabetes models also showed that chronic GAGs administration can reduce albuminuria and prevent some renal morphological and functional alterations [9] . In human diabetic nephropathy, GMB alterations are markedly correlated with expansion of the mesangial area. On the other hand GAGs can inhibit mesangial cells growth, interfere with growth factors, and modulate synthesis of extracellular matrix proteins in cells of mesenchymal origin [8, 15] .
The above data may indirectly support the hypothesis that the derangement in GAG metabolism may have a pathogenetic role in the onset of diabetic nephropathy, through the induction of a biochemical derangement in GBM composition [26 ] .
In diabetic patients with albuminuria, a favourable effect on AER has been recently reported by Myrup et al. [12 ] and by Tamsma et al. [13 ] with the use of low-molecular-weight heparins and by Solini et al. [11] and Velussi et al. [14 ] with sulodexide.
In our study sulodexide administration significantly reduced AER in type I diabetic patients both with micro-and with macroalbuminuria, while placebotreated micro-and macroalbuminurics did not evidence AER variations. This behaviour was not related with changes of metabolic control, blood pressure, and diet; and/or to the different administration scheme adopted (parenteral sulodexide in our study and oral sulodexide neither plasma glucose nor glycated haemoglobin showed any variation during both placebo and sulodex-in the Solini trial ). In our study another difference between micro-and macroalbuminurics was that the ide treatment. No symptomatic urinary tract infection, another parameter influencing AER, was ever observed AER reduction registered at the end of treatment in microalbuminuric patients was maintained during the during the study; at the same time the administration scheme for insulin therapy remained unmodified in all 6 weeks of follow-up, while in macroalbuminurics AER was found in the end again appreciably increased, the patients.
Solini et al.
[11] described in their small study group independently of metabolic control, systolic and diastolic blood pressure, sex distribution, and body a different trend in microalbuminuric with respect to macroalbuminuric patients, the latter showing a higher weight, since all these parameters were initially similar and did not vary as a consequence of treatment. AER decrease than the former. The opposite was registered in our study: the percentage of AER decrease It is, on the other hand, possible that depending on the severity of albuminuria, different GAG dosages in microalbuminuric patients was significantly higher than in macroalbuminurics. Such differing study results must be administered, so that dosages suitable for microalbuminuric patients could be insufficient for may be due to the different type of patients (type I diabetics in our study and type II in Solini's trial ), macroalbuminurics. Furthermore, since an abnormal GAG metabolism is detectable not only at the kidney functional renal alterations that occur in diabetic nephropathy. level but also on all the other vessel walls [28 ] , in macroalbuminuric patients GAG synthesis may be greatly compromised not only in GBM but also at the vessels level, and the administered sulodexide could be References captured by all the vessel surfaces and therefore attain 
